Protein Kinase Inhibitors
"Protein Kinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit PROTEIN KINASES.
| Descriptor ID |
D047428
|
| MeSH Number(s) |
D27.505.519.389.755
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Protein Kinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Protein Kinase Inhibitors".
This graph shows the total number of publications written about "Protein Kinase Inhibitors" by people in this website by year, and whether "Protein Kinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 2 | 2 |
| 2006 | 1 | 3 | 4 |
| 2007 | 4 | 5 | 9 |
| 2008 | 3 | 14 | 17 |
| 2009 | 5 | 3 | 8 |
| 2010 | 8 | 12 | 20 |
| 2011 | 6 | 7 | 13 |
| 2012 | 9 | 6 | 15 |
| 2013 | 8 | 14 | 22 |
| 2014 | 18 | 8 | 26 |
| 2015 | 16 | 5 | 21 |
| 2016 | 20 | 12 | 32 |
| 2017 | 15 | 13 | 28 |
| 2018 | 22 | 7 | 29 |
| 2019 | 14 | 12 | 26 |
| 2020 | 14 | 11 | 25 |
| 2021 | 22 | 12 | 34 |
| 2022 | 2 | 19 | 21 |
| 2023 | 3 | 18 | 21 |
| 2024 | 18 | 7 | 25 |
| 2025 | 27 | 9 | 36 |
| 2026 | 16 | 0 | 16 |
To return to the timeline,
click here.
Below are the most recent publications written about "Protein Kinase Inhibitors" by people in Profiles.
-
Real-world efficacy and safety of CDK4/6 inhibitors plus endocrine therapy in HR+/HER2?-?metastatic breast cancer: a single-institution experience. J Egypt Natl Canc Inst. 2026 Jul 28; 38(1).
-
Tolebrutinib liver safety: A detailed overview. Mult Scler Relat Disord. 2026 Sep; 113:107404.
-
Personalized targeting of BCL2 family proteins overcomes acquired resistance to BRAF-MEK inhibitors in preclinical melanoma. Nat Commun. 2026 Jun 26; 17(1).
-
Structural Transformation of a BRAF Inhibitor into a Selective PKR Inhibitor. J Med Chem. 2026 Jul 09; 69(13):15227-15246.
-
CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials. Lancet Oncol. 2026 May; 27(5):592-603.
-
Dissecting Pirtobrutinib Resistance in Mantle Cell Lymphoma Through Single-Cell Multi-Omics. Am J Hematol. 2026 Jul; 101(7):1632-1649.
-
Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study. Blood Adv. 2026 Apr 14; 10(7):2441-2451.
-
Nanoscale Direct-to-Biology Optimization of Cdk2 Inhibitors. J Med Chem. 2026 Apr 23; 69(8):9142-9162.
-
Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomes. Leukemia. 2026 May; 40(5):946-954.
-
Ocular Surface Ulceration Associated With an Epidermal Growth Factor Receptor Inhibitor. Cornea. 2026 Jul 01; 45(7):937-939.